3/24
08:00 am
coya
ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COO
Medium
Report
ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COO
3/23
08:04 am
coya
Coya Therapeutics (COYA) had its "buy" rating reaffirmed by HC Wainwright. They now have a $18.00 price target on the stock.
Low
Report
Coya Therapeutics (COYA) had its "buy" rating reaffirmed by HC Wainwright. They now have a $18.00 price target on the stock.
3/21
01:31 am
coya
Low
Report
3/18
08:00 am
coya
Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy
Low
Report
Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy
3/16
03:21 pm
coya
Coya Therapeutics (COYA) had its "buy" rating reaffirmed by Chardan Capital. They now have a $14.00 price target on the stock.
Low
Report
Coya Therapeutics (COYA) had its "buy" rating reaffirmed by Chardan Capital. They now have a $14.00 price target on the stock.
3/16
03:21 pm
coya
Coya Therapeutics (COYA) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $15.00 price target on the stock.
Low
Report
Coya Therapeutics (COYA) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $15.00 price target on the stock.
3/16
08:00 am
coya
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results
Neutral
Report
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results
2/18
08:13 am
coya
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
Medium
Report
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
2/10
08:27 am
coya
Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial [Yahoo! Finance]
Low
Report
Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial [Yahoo! Finance]
2/10
08:00 am
coya
Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial
Low
Report
Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial
2/2
08:05 am
coya
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Low
Report
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
1/31
08:44 am
coya
Coya Therapeutics to sell 2.522M shares at $4.40 in private placement [Yahoo! Finance]
Medium
Report
Coya Therapeutics to sell 2.522M shares at $4.40 in private placement [Yahoo! Finance]
1/30
08:47 am
coya
Coya Therapeutics Announces $11.1 Million Private Placement [Yahoo! Finance]
Low
Report
Coya Therapeutics Announces $11.1 Million Private Placement [Yahoo! Finance]
1/30
08:00 am
coya
Coya Therapeutics Announces $11.1 Million Private Placement
Neutral
Report
Coya Therapeutics Announces $11.1 Million Private Placement
1/21
08:00 am
coya
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
Low
Report
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
1/20
08:00 am
coya
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
Medium
Report
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
1/8
05:14 pm
coya
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.
Medium
Report
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.
1/8
08:00 am
coya
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients
Low
Report
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients
1/5
08:33 am
coya
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
Medium
Report
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
1/5
08:00 am
coya
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)
Medium
Report
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)